201 related articles for article (PubMed ID: 35896612)
1. Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.
Zhang H; Liu M; Yang Z; Du G; Yu B; Gui Y; Cao L; Li X; Tan B
Sci Rep; 2022 Jul; 12(1):12785. PubMed ID: 35896612
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
[TBL] [Abstract][Full Text] [Related]
3. m
Xu F; Huang X; Li Y; Chen Y; Lin L
Mol Ther Nucleic Acids; 2021 Jun; 24():780-791. PubMed ID: 33996259
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
Sun D; Zhang C
Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
[TBL] [Abstract][Full Text] [Related]
5. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
6. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
8. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
9. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
11. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
13. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
14. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
15. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.
Zhou Q; Xiong J; Gao Y; Yi R; Xu Y; Chen Q; Wang L; Chen Y
Funct Integr Genomics; 2023 Oct; 23(4):323. PubMed ID: 37864709
[TBL] [Abstract][Full Text] [Related]
16. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
17. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
18. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
20. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]